Kevin T Ousdigian1, P Peter Borek2, Jodi L Koehler2, J Thomas Heywood2, Paul D Ziegler2, Bruce L Wilkoff2. 1. From the Medtronic, Inc, Minneapolis, MN (K.T.O., J.L.K., P.D.Z.); Centennial Heart, Nashville, TN (P.P.B.); Scripps Clinic, San Diego, CA (J.T.H.); and Cleveland Clinic Foundation, OH (B.L.W.). kevin.ousdigian@gmail.com. 2. From the Medtronic, Inc, Minneapolis, MN (K.T.O., J.L.K., P.D.Z.); Centennial Heart, Nashville, TN (P.P.B.); Scripps Clinic, San Diego, CA (J.T.H.); and Cleveland Clinic Foundation, OH (B.L.W.).
Abstract
BACKGROUND: We classified patients' atrial fibrillation (AF), assessed its impact on biventricular pacing (BIVP%), and determined whether AF classification or BIVP% independently correlate with mortality in cardiac resynchronization therapy defibrillator patients. METHODS AND RESULTS: Cardiac resynchronization therapy defibrillator patients were classified as permanent (daily mean AF burden ≥23 hours), persistent (≥7 consecutive days of AF ≥23 hours/d), paroxysmal (≥1 day with AF ≥6 hours), or no/little AF (all others) using device-detected AF during the 6 months postimplant. We evaluated subsequent all-cause mortality using a multivariable Cox proportional hazard regression. Among 54 019 patients (age, 70±11 years; 73% male; follow-up, 2.3±1.2 years), 8% of patients each had permanent (N=4449), persistent (N=4237), and paroxysmal AF (N=4219). A high proportion of patients with permanent (69%) and persistent (62%) AF did not achieve high BIVP (>98%). Relative to no/little AF, patients with AF had increased mortality after adjusting for age, sex, BIVP, and shocks (permanent: hazard ratio=1.28 [1.19-1.38]; P<0.001; persistent: hazard ratio=1.51 [1.41-1.61]; P<0.001). Relative to patients with BIVP >98%, patients with reduced BIVP had increased mortality after adjusting for age, sex, AF, and shocks (90%-98%: hazard ratio=1.20 [1.15-1.26]; P<0.001; <90%: hazard ratio=1.32 [1.23-1.41]; P<0.001). High BIVP% was associated with the greatest mortality improvement in permanent AF among the AF classifications. CONCLUSIONS: High BIVP% was not achieved in two thirds of 8686 patients with persistent or permanent AF, and these patients had an increased risk of death. A shift toward more aggressive rate control and more pacing may be necessary in patients with AF to maximize the benefits of cardiac resynchronization therapy.
BACKGROUND: We classified patients' atrial fibrillation (AF), assessed its impact on biventricular pacing (BIVP%), and determined whether AF classification or BIVP% independently correlate with mortality in cardiac resynchronization therapy defibrillator patients. METHODS AND RESULTS: Cardiac resynchronization therapy defibrillator patients were classified as permanent (daily mean AF burden ≥23 hours), persistent (≥7 consecutive days of AF ≥23 hours/d), paroxysmal (≥1 day with AF ≥6 hours), or no/little AF (all others) using device-detected AF during the 6 months postimplant. We evaluated subsequent all-cause mortality using a multivariable Cox proportional hazard regression. Among 54 019 patients (age, 70±11 years; 73% male; follow-up, 2.3±1.2 years), 8% of patients each had permanent (N=4449), persistent (N=4237), and paroxysmal AF (N=4219). A high proportion of patients with permanent (69%) and persistent (62%) AF did not achieve high BIVP (>98%). Relative to no/little AF, patients with AF had increased mortality after adjusting for age, sex, BIVP, and shocks (permanent: hazard ratio=1.28 [1.19-1.38]; P<0.001; persistent: hazard ratio=1.51 [1.41-1.61]; P<0.001). Relative to patients with BIVP >98%, patients with reduced BIVP had increased mortality after adjusting for age, sex, AF, and shocks (90%-98%: hazard ratio=1.20 [1.15-1.26]; P<0.001; <90%: hazard ratio=1.32 [1.23-1.41]; P<0.001). High BIVP% was associated with the greatest mortality improvement in permanent AF among the AF classifications. CONCLUSIONS: High BIVP% was not achieved in two thirds of 8686 patients with persistent or permanent AF, and these patients had an increased risk of death. A shift toward more aggressive rate control and more pacing may be necessary in patients with AF to maximize the benefits of cardiac resynchronization therapy.
Authors: Jakob Lüker; Georg von Bodman; Arian Sultan; Jürgen Brömsen; Ruken Ö Akbulak; Benjamin Schäffer; Doreen Schreiber; Boris A Hoffmann; Michael Block; Stephan Willems; Daniel Steven Journal: Clin Res Cardiol Date: 2014-12-04 Impact factor: 5.460
Authors: Victor Nauffal; Tanyanan Tanawuttiwat; Yiyi Zhang; John Rickard; Joseph E Marine; Barbara Butcher; Sanaz Norgard; Timm Dickfeld; Kenneth A Ellenbogen; Eliseo Guallar; Gordon F Tomaselli; Alan Cheng Journal: Heart Rhythm Date: 2015-07-17 Impact factor: 6.343
Authors: Antonius M W van Stipdonk; Stijn Schretlen; Wim Dohmen; Christian Knackstedt; Fabienne Beckers-Wesche; Luuk Debie; Hans-Peter Brunner-La Rocca; Kevin Vernooy Journal: ESC Heart Fail Date: 2022-05-31
Authors: Vinod Sharma; Lisa D Rathman; Roy S Small; David J Whellan; Jodi Koehler; Eduardo Warman; William T Abraham Journal: Heart Lung Date: 2014-12-24 Impact factor: 2.210
Authors: Bruce L Wilkoff; Laurent Fauchier; Martin K Stiles; Carlos A Morillo; Sana M Al-Khatib; Jesœs Almendral; Luis Aguinaga; Ronald D Berger; Alejandro Cuesta; James P Daubert; Sergio Dubner; Kenneth A Ellenbogen; N A Mark Estes; Guilherme Fenelon; Fermin C Garcia; Maurizio Gasparini; David E Haines; Jeff S Healey; Jodie L Hurtwitz; Roberto Keegan; Christof Kolb; Karl-Heinz Kuck; Germanas Marinskis; Martino Martinelli; Mark McGuire; Luis G Molina; Ken Okumura; Alessandro Proclemer; Andrea M Russo; Jagmeet P Singh; Charles D Swerdlow; Wee Siong Teo; William Uribe; Sami Viskin; Chun-Chieh Wang; Shu Zhang Journal: J Arrhythm Date: 2016-02-01